Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset - HMS LINCS Database

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)

Download: Excel (XLSX), Comma-separated (CSV)

Filter results: >>>>

|<
<<
Previous
Page 11 of 18
Next
>>
>
251 to 275 of 432 records
per page:

Cell line	Drug name	Experimental replicate	Timepoint	Curve type (GR values)	Curve type (relative cell counts)	Experiment name	Number of concentrations	Cell doublings (DMSO control)	GR50	GRmax	GR_AOC	GEC50	GRinf	Hill slope (GR values)	R-squared sigmoid fit (GR values)	P-value sigmoid fit (GR values)	R-squared flat fit (GR values)	IC50	Emax	AUC	EC50	Einf	Hill slope (relative cell counts)	R-squared sigmoid fit (relative cell counts)	P-value sigmoid fit (relative cell counts)	R-squared flat fit (relative cell counts)
HCC70	Alpelisib	1	72	sigmoid	sigmoid	HCC70 alpelisib 0 1 72	8	1.383	4.4	0.574	0.105	20.4	-1.0	0.717	0.78	0.0106	NA	11.9	0.718	0.929	11.9	0.0	0.732	0.768	0.0124	NA
Hs 578T	Buparlisib	1		sigmoid	sigmoid	Hs578T buparlisib 1	8	2.064	0.55	-0.579	0.308	1.29	-1.0	1.29	0.992	4.22e-07	NA	0.587	0.0401	0.759	0.587	0.0	1.31	0.988	1.94e-06	NA
HCC38	Everolimus	2	72	sigmoid	flat	HCC38 everolimus 0 2 72	8	2.170	8323.0	0.58	0.376	0.000127	0.417	0.1	0.688	0.0303	NA	Inf	0.6	0.637	0.0	0.6	0.01	0.509	0.119	0.637
HCC70	AS605240	3	72	sigmoid	sigmoid	HCC70 AS-605240 0 3 72	8	2.447	Inf	0.58	0.112	0.427	0.549	1.18	0.985	3.24e-06	NA	Inf	0.562	0.877	0.345	0.544	1.24	0.982	6.14e-06	NA
BT-20	Omipalisib	3	72	sigmoid	sigmoid	BT20 omipalisib 0 3 72	8	2.586	0.00689	-0.587	0.893	0.044	-0.714	0.478	0.958	7.32e-05	NA	0.00572	0.017	0.281	0.00491	0.0669	0.945	0.983	4.7e-06	NA
Hs 578T	Sirolimus	1		sigmoid	sigmoid	Hs578T rapamycin 1	8	2.013	110643.0	0.587	0.358	0.000237	0.432	0.1	0.879	0.00178	NA	9.61e+11	0.628	0.672	0.000175	0.487	0.1	0.851	0.00332	NA
Hs 578T	AS605240	3		sigmoid	sigmoid	Hs578T AS-605240 3	8	2.856	63.8	0.588	0.0965	0.826	0.494	1.03	0.983	4.89e-06	NA	5.75	0.518	0.879	0.552	0.465	1.14	0.981	6.87e-06	NA
HCC38	Sirolimus	2	72	flat	flat	HCC38 rapamycin 0 2 72	8	2.106	Inf	0.588	0.371	0.0	0.588	0.01	0.496	0.128	0.629	Inf	0.616	0.65	0.0	0.616	0.01	0.246	0.429	0.649
HCC70	WYE-125132	3	72	sigmoid	sigmoid	HCC70 WYE-132 0 3 72	8	2.417	Inf	0.592	0.246	0.0209	0.606	1.64	0.995	1.48e-07	NA	Inf	0.576	0.739	0.019	0.588	1.64	0.996	7.52e-08	NA
HCC1806	AZD8055	3	72	sigmoid	sigmoid	HCC1806 AZD8055 0 3 72	8	3.185	Inf	0.593	0.215	0.0523	0.583	1.19	0.995	1.36e-07	NA	0.521	0.484	0.716	0.0427	0.471	1.15	0.996	7.15e-08	NA
BT-549	Trametinib	1	72	sigmoid	sigmoid	BT549 trametinib 0 1 72	8	1.812	Inf	0.596	0.202	0.131	0.523	0.61	0.959	6.65e-05	NA	28.3	0.664	0.828	3.47	0.254	0.337	0.933	0.000305	NA
HCC38	PIK-93	3	72	sigmoid	sigmoid	HCC38 PIK-93 0 3 72	8	1.382	5.05	0.598	0.061	2.34	0.358	1.63	0.919	0.000533	NA	Inf	0.734	0.959	2.23	0.586	1.64	0.914	0.000645	NA
BT-549	Trametinib	2	72	sigmoid	sigmoid	BT549 trametinib 0 2 72	8	1.914	Inf	0.602	0.2	0.0685	0.581	0.837	0.995	1.05e-07	NA	Inf	0.654	0.822	0.0601	0.638	0.839	0.995	1.04e-07	NA
Hs 578T	AZD-6482	2		sigmoid	sigmoid	Hs578T AZD6482 2	8	2.508	6.35	0.602	0.121	74.8	-1.0	0.445	0.998	1.12e-08	NA	6.4	0.573	0.86	6.4	0.0	0.475	0.996	6.36e-08	NA
HCC1806	ZSTK474	1	72	sigmoid	sigmoid	HCC1806 ZSTK474 0 1 72	8	2.709	Inf	0.602	0.037	1.17	0.599	4.88	0.99	1.12e-06	NA	Inf	0.548	0.958	1.12	0.545	4.88	0.985	3.14e-06	NA
Hs 578T	MK2206	1		sigmoid	sigmoid	Hs578T MK-2206 1	8	2.039	Inf	0.608	0.165	0.087	0.665	2.09	0.9	0.00101	NA	Inf	0.641	0.845	0.0803	0.689	1.9	0.908	0.000775	NA
HCC38	PIK-93	1	72	sigmoid	sigmoid	HCC38 PIK-93 0 1 72	8	1.741	5.24	0.61	0.0782	24.5	-1.0	0.713	0.982	6.07e-06	NA	9.93	0.686	0.935	9.93	0.0	0.729	0.979	9.08e-06	NA
HCC1806	ZSTK474	2	72	sigmoid	sigmoid	HCC1806 ZSTK474 0 2 72	8	2.794	Inf	0.613	0.036	1.16	0.61	5.0	0.99	1.1e-06	NA	Inf	0.548	0.958	1.12	0.545	4.88	0.985	3.14e-06	NA
BT-549	AZD-6482	3	72	sigmoid	sigmoid	BT549 AZD6482 0 3 72	8	1.744	8.87	0.616	0.0979	2.2	0.324	0.749	0.993	2.93e-07	NA	115.0	0.69	0.918	1.91	0.476	0.744	0.993	4.19e-07	NA
HCC70	CAL-101	2	72	sigmoid	sigmoid	HCC70 idelalisib 0 2 72	8	1.738	Inf	0.62	0.0432	0.959	0.611	3.13	0.965	4.31e-05	NA	Inf	0.693	0.965	0.935	0.686	3.13	0.96	6.52e-05	NA
HCC38	Pictilisib	2	72	sigmoid	sigmoid	HCC38 pictilisib 0 2 72	8	2.112	Inf	0.622	0.0838	0.644	0.58	1.32	0.933	0.000298	NA	Inf	0.642	0.918	0.568	0.612	1.36	0.922	0.000475	NA
Hs 578T	Sirolimus	2		flat	flat	Hs578T rapamycin 2	8	2.536	Inf	0.623	0.341	0.0	0.623	0.01	0.16	0.593	0.66	Inf	0.589	0.623	0.0	0.589	0.01	-0.232	1.0	0.624
HCC38	Torin2	3	72	sigmoid	sigmoid	HCC38 Torin2 0 3 72	8	1.385	0.013	-0.624	0.855	0.0547	-0.706	0.615	0.996	8.13e-08	NA	0.0407	0.0986	0.484	0.0311	0.0829	0.669	0.997	3.31e-08	NA
Hs 578T	Everolimus	1		sigmoid	sigmoid	Hs578T everolimus 1	8	2.030	1707115.0	0.626	0.318	0.00576	0.429	0.1	0.895	0.00116	NA	2.51e+21	0.657	0.704	0.00121	0.502	0.1	0.893	0.00124	NA
Hs 578T	Everolimus	2		sigmoid	sigmoid	Hs578T everolimus 2	8	2.550	3210000000.0	0.626	0.335	0.000205	0.476	0.1	0.791	0.00913	NA	18938.0	0.59	0.627	0.000153	0.422	0.1	0.745	0.0166	NA

|<
<<
Previous
Page 11 of 18
Next
>>
>
251 to 275 of 432 records
per page:

HMS LINCS Project

Evaluation of the sensitivities of six triple-negative breast cancer (TNBC) cell lines to 23 different PI3K/AKT/mTOR inhibitors or to a MEK inhibitor (trametinib). Dataset 2 of 2: GR metrics. - Dataset (ID:20365)